Akums Drugs and Pharmaceuticals Limited Q4 FY25 earnings call summary

Earnings call of 27 May 2025, summarised by AI from the filing.

Akums Q4 FY25 total income rose 12.4% to ₹1,073 cr; FY26 volume growth guided at single-high-digit.

Key takeaways

1. Guidance FY26 volume growth expected single-high-digit; CDMO margins similar; API losses to reduce.
2. Driver CDMO volume growth and niche product mix, with 31 DCGI launches in FY25.
3. Risk API price erosion continues, impacting CDMO business and delaying API turnaround.

Original filing on BSE

Akums Drugs and Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹1,167 cr (+14% year on year), EBITDA ₹175 cr (+35% year on year), PAT ₹101 cr (+55% year on year), EBITDA margin 15.0% (+238 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹1,158 cr (+10% year on year), EBITDA ₹152 cr (+61% year on year), PAT ₹81.3 cr (−46% year on year), EBITDA margin 13.1% (+420 bps). Score 49 of 100, In line with trend. EBITDA margin rose 420 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +15.3% in 29 days (Nifty 500: +1.0%).
• Q3 FY26: Revenue ₹1,160 cr (+15% year on year), EBITDA ₹147 cr (+21% year on year), PAT ₹67.7 cr (+37% year on year), EBITDA margin 12.7% (+68 bps). Score 53 of 100, In line with trend. EBITDA margin rose 68 bps year on year. Other income 34% of PBT. Consolidated profit +3% but standalone -31%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.6% in 30 days (Nifty 500: −1.1%).
• Q2 FY26: Revenue ₹1,018 cr (−1% year on year), EBITDA ₹95.0 cr (−22% year on year), PAT ₹43.0 cr (−36% year on year), EBITDA margin 9.3% (−248 bps). Score 7 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone. Profit fell 34% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: −0.4%).
• Q1 FY26: Revenue ₹1,024 cr (0% year on year), EBITDA ₹129 cr (+2% year on year), PAT ₹65.0 cr (+7% year on year), EBITDA margin 12.6% (+13 bps). Score 28 of 100, Below trend. EBITDA margin rose 13 bps year on year. Other income 28% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −4.2% in 28 days (Nifty 500: +1.7%).
• Q4 FY25: Revenue ₹1,056 cr, EBITDA ₹94.0 cr, PAT ₹150 cr, EBITDA margin 8.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,056 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −1.1% in 30 days (Nifty 500: +1.7%).
• Q3 FY25: Revenue ₹1,010 cr, EBITDA ₹121 cr, PAT ₹66.0 cr, EBITDA margin 12.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,010 cr). Scored once a year-earlier consolidated quarter exists.
• Q2 FY25: Revenue ₹1,033 cr, EBITDA ₹122 cr, PAT ₹67.0 cr, EBITDA margin 11.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,033 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Akums Drugs and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (8 Aug 2026)
• Q4 FY26: Earnings call (18 May 2026), Results deck (14 May 2026)
• Q3 FY26: Earnings call (16 Feb 2026), Results deck (13 Feb 2026)
• Q2 FY26: Earnings call (14 Nov 2025), Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (11 Aug 2025), Results deck (8 Aug 2025)
• Q4 FY25: Earnings call (27 May 2025), Results deck (26 May 2025)